Targetable Gene Fusions Associate With the IDH Wild-Type Astrocytic Lineage in Adult Gliomas

Abstract Gene fusions involving oncogenes have been reported in gliomas and may serve as novel therapeutic targets. Using RNA-sequencing, we interrogated a large cohort of gliomas to assess for the incidence of targetable genetic fusions. Gliomas (n = 390) were profiled using the ArcherDx FusionPlex Assay. Fifty-two gene targets were analyzed and fusions with preserved kinase domains were investigated. Overall, 36 gliomas (9%) harbored a total of 37 potentially targetable fusions, the majority of which were found in astrocytomas (n = 34). Within this lineage 11% (25/235) of glioblastomas, 12% (5/42) of anaplastic astrocytomas, 8% (2/25) of grade II astrocytomas, and 33% (2/6) of pilocytic astrocytoma harbored targetable fusions. Fusions were significantly more frequent in IDH wild-type tumors (12%, n = 31/261) relative to IDH mutants (4%; n = 4/109) (p = 0.011). No fusions were seen in oligodendrogliomas. The most frequently observed therapeutically targetable fusions were in FGFR (n = 12), MET (n = 11), and NTRK (n = 8). Several additional novel fusions that have not been previously described in gliomas were identified including EGFR:VWC2 and FGFR3:NBR1. In summary, targetable gene fusions are enriched in IDH wild-type high-grade astrocytic tumors, which will influence enrollment in and interpretation of clinical trials of glioma patients.

[1]  A. Drilon,et al.  Somatic chromosomal engineering identifies BCAN-NTRK1 as a potent glioma driver and therapeutic target , 2017, Nature Communications.

[2]  J. Swensen,et al.  RNA-Seq analysis of glioma tumors to reveal targetable gene fusions. , 2017 .

[3]  Roland Eils,et al.  Recurrent MET fusion genes represent a drug target in pediatric glioblastoma , 2016, Nature Medicine.

[4]  G. Steinberg,et al.  Molecular Drivers of the Non–T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer , 2016, Cancer Immunology Research.

[5]  Yanjun Qi,et al.  Recurrent chimeric fusion RNAs in non-cancer tissues and cells , 2016, Nucleic acids research.

[6]  Steven J. M. Jones,et al.  Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma , 2016, Cell.

[7]  C. Sarkar,et al.  Oncogenic KIAA1549-BRAF fusion with activation of the MAPK/ERK pathway in pediatric oligodendrogliomas. , 2015, Cancer genetics.

[8]  P. Burger,et al.  High rate of concurrent BRAF-KIAA1549 gene fusion and 1p deletion in disseminated oligodendroglioma-like leptomeningeal neoplasms (DOLN) , 2015, Acta Neuropathologica.

[9]  A. Iavarone,et al.  Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma , 2015, Clinical Cancer Research.

[10]  J. Akers,et al.  RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas , 2014, Genome research.

[11]  Amar Gajjar,et al.  The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma , 2014, Nature Genetics.

[12]  Jinkuk Kim,et al.  NTRK1 Fusion in Glioblastoma Multiforme , 2014, PloS one.

[13]  Wei Zhang,et al.  Fusion genes in solid tumors: an emerging target for cancer diagnosis and treatment , 2013, Chinese journal of cancer.

[14]  D. Haussler,et al.  The Somatic Genomic Landscape of Glioblastoma , 2013, Cell.

[15]  Raul Rabadan,et al.  The integrated landscape of driver genomic alterations in glioblastoma , 2013, Nature Genetics.

[16]  Michael Thomas,et al.  Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. , 2013, The New England journal of medicine.

[17]  Nickolay A. Khazanov,et al.  Identification of targetable FGFR gene fusions in diverse cancers. , 2013, Cancer discovery.

[18]  M. Nykter,et al.  The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. , 2013, The Journal of clinical investigation.

[19]  M. Knowles,et al.  Oncogenic FGFR3 gene fusions in bladder cancer , 2012, Human molecular genetics.

[20]  R. Lothe,et al.  Survey of 548 oncogenic fusion transcripts in thyroid tumors supports the importance of the already established thyroid fusions genes , 2012, Genes, chromosomes & cancer.

[21]  D. Brat,et al.  Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma , 2012, Science.

[22]  Kristian Cibulskis,et al.  Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion , 2011, Nature Genetics.

[23]  C. Brennan,et al.  PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas. , 2010, Genes & development.

[24]  R. McLendon,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[25]  P. Kleihues,et al.  IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. , 2009, The American journal of pathology.

[26]  A. Vincent-Salomon,et al.  Secretory breast carcinomas with ETV6-NTRK3 fusion gene belong to the basal-like carcinoma spectrum , 2009, Modern Pathology.

[27]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[28]  J. Tchinda,et al.  Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer , 2005, Science.

[29]  Keara M. Lane,et al.  Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21) , 2003, Genes, chromosomes & cancer.